✦ LIBER ✦

Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP

✍ Scribed by Min Kyoung Kim; Shin Kim; Sung Sook Lee; Sun Jin Sym; Dae Ho Lee; Sang We Kim; Seongsoo Jang; Chan Jeong Park; Hyun Sook Chi; Jooryung Huh; Cheolwon Suh

Book ID: 109143674
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 163 KB
Volume: 47
Category: Article
ISSN: 0372-1248
DOI: 10.1111/j.1537-2995.2007.01285.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

R-ESHAP plus pegfilgrastim as an effecti

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

✍ Montoro, Juan; Andreola, Giovanna; Gardellini, Angelo; Babic, Aleksandra; Negri, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 406 KB

Efficacy and Safety of Rituximab Combine

Efficacy and Safety of Rituximab Combined with ESHAP Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

✍ Harting, Rekha; Venugopal, Parameswaran; Gregory, Stephanie A.; O'Brien, Teresa; 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 168 KB

ESHAP+fixed dose G-CSF as autologous per

ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

✍ Akhtar, S; Tbakhi, A; Humaidan, H; El Weshi, A; Rahal, M; Maghfoor, I 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 135 KB

Bendamustine combined with rituximab for

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

✍ Vacirca, Jeffrey L.; Acs, Peter. I.; Tabbara, Imad A.; Rosen, Peter. J.; Lee, Pe 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 339 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

A pilot study of cyclophosphamide, carbo

A pilot study of cyclophosphamide, carboplatin, etoposide (CCE), and G-CSF with or without rituximab for cytoreduction and peripheral blood stem cell mobilization in patients with relapsed or refractory lymphomas

✍ D.E. Stevenson; A.L. Haroff; D.W. Ririe; J.E. Splichal; D.L. Ornstein; B.J. Hell 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB